| 查看: 2122 | 回复: 11 | |||||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||||
[交流]
GSK被调查，会对医药行业各个产业链产生什么影响已有11人参与
|
|||||
| 大家都来深入浅出的分析一下 |
回复此楼» 收录本帖的淘帖专辑推荐
 新药研发必备资料 | 行业动态 |
» 猜你喜欢
数据驱动智能故障诊断技术应用与实践
已经有0人回复
-
基于AI智能算法的装备结构可靠性分析与优化设计技术
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有81人回复
-
26在职申博—生物与医药—抗体/ADC药物方向，江浙沪，有项目，可带资。
已经有1人回复
-
求助求助
已经有0人回复
-
农业资源与环境、智慧农业专业本科生毕业论文课题选题求助
已经有1人回复
-
人工智能赋能聚合物及复合材料模型应用与实践
已经有0人回复
-
各国和国际组织现行药典注射用水质量标准
已经有0人回复
-
求助用微谱数据库查询
已经有0人回复
-
计算化学与人工智能驱动的MOFs性能预测与筛选技术
已经有0人回复
-
研三实验求指导
已经有0人回复
» 本主题相关商家推荐: (我也要在这里推广)
先是网上报纸上骂声一片，然后砖家出来澄清，然后。。。。。就没有然后了。
4楼2013-07-17 14:33:25
2楼2013-07-17 13:17:45
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
柳叶刀文章，转自丁香园，分析GSK事件，说中国医患问题可能与医生和某些药企的不健康关系有关，请看下文： Doctors and pharma in China The Lancet Doctor—patient relationships in China are in crisis. Doctors have been injured or even killed by patients at work. One of the major drivers might be the unhealthy and unethical relations between many doctors and some drug companies. On July 8, GlaxoSmithKline (GSK) said that they were investigating allegations that its staff had improperly used cash and other incentives to encourage the prescription of onabotulinumtoxin A (Botox) in China. The company added that “inquiries to date have found no evidence of bribery or corruption in relation to our sales and marketing of therapeutic Botox in China.” The Lancet has no evidence to suggest that the allegations against GSK in China are true. However, some observers claim that bribing doctors to boost drug prescriptions by some drug companies is an open secret, and that this alleged practice has compromised the public's trust in doctors. The varieties of unethical relationships that exist between some doctors and some of the drug companies in China are said to range from cash kickbacks, lavish gifts or entertainment, ghost writing services, sponsored supplements in journals, and all-expenses-paid trips. There is real concern that doctors' prescriptions are therefore not based solely on patient need and clinical evidence, but may be biased by commercial interests. The perceived unethical association between physicians and industry in China is worrying, because it inevitably harms patients as well as doctors. It damages the doctor—patient relationship and, ultimately, China's whole health system. The GSK China allegations, although unproven, have clearly rung an alarm bell for China's regulatory authorities to ensure the drug industry promotes products in a responsible, ethical, and professional way. Chinese doctors should rely on evidence-based clinical guidelines to inform their practice, and are in urgent need of guidance on their collaborations with the drug industry in various areas such as patient care, professional education, and research. Furthermore, training for doctors in China on managing their relationships ethically with the drug industry and other organisations should start at medical school and be part of continuing professional education. |
3楼2013-07-17 14:31:18
5楼2013-07-17 19:26:08